Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
143.2 INR | -0.52% |
|
-0.62% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: Marzo | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 263.8 | 303.6 | 594.8 | 616.4 |
EBITDA 1 | 10.63 | 15.35 | 65.03 | 79.46 |
EBIT 1 | 7.211 | 11.41 | 60.43 | 73.96 |
Operating Margin | 2.73% | 3.76% | 10.16% | 12% |
Earnings before Tax (EBT) 1 | 4.221 | 8.479 | 57.85 | 69.6 |
Net income 1 | 2.862 | 6.547 | 41.66 | 50.28 |
Net margin | 1.08% | 2.16% | 7% | 8.16% |
EPS 2 | 2.650 | 0.6069 | 3.862 | 4.661 |
Free Cash Flow | - | - | 6.186 | -8.198 |
FCF margin | - | - | 1.04% | -1.33% |
FCF Conversion (EBITDA) | - | - | 9.51% | - |
FCF Conversion (Net income) | - | - | 14.85% | - |
Dividend per Share | - | - | - | - |
Announcement Date | 30/04/24 | 02/09/22 | 02/09/22 | 04/03/24 |
Balance Sheet Analysis
Fiscal Period: Maart | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | 26.2 | 29.4 | 30.6 | 16 |
Net Cash position 1 | - | - | - | - |
Leverage (Debt/EBITDA) | 2.466 x | 1.915 x | 0.4711 x | 0.2014 x |
Free Cash Flow | - | - | 6.19 | -8.2 |
ROE (net income / shareholders' equity) | - | - | 52.3% | 40.2% |
ROA (Net income/ Total Assets) | - | - | 14.1% | 11.4% |
Assets 1 | - | - | 295.2 | 443 |
Book Value Per Share 2 | 48.50 | 5.460 | 9.320 | 13.90 |
Cash Flow per Share 2 | 1.210 | 0.0900 | 0.0600 | 2.310 |
Capex 1 | 7.32 | - | 19.3 | 30.7 |
Capex / Sales | 2.77% | - | 3.25% | 4.98% |
Announcement Date | 30/04/24 | 02/09/22 | 02/09/22 | 04/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- QUESTLAB Stock
- Financials Quest Laboratories Limited